ProShare Advisors
CRDF icon

ProShare Advisors’s Cardiff Oncology CRDF Stock Holding History

ProShare Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,328
Closed -$31.8K – 1907
2025
Q4 		$31.8K Buy
11,328
+728
+7% +$1.69K ﹤0.01% 1995
2025
Q3 		$21.8K Sell
10,600
-2,112
-17% -$5.84K ﹤0.01% 1988
2025
Q2 		$40K Buy
12,712
+94
+0.7% +$287 ﹤0.01% 2022
2025
Q1 		$39.6K Buy
12,618
+1,132
+10% +$4.48K ﹤0.01% 1977
2024
Q4 		$49.9K Buy
+11,486
New +$35.9K ﹤0.01% 2176

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

ProShare Advisors's CRDF Position: Q1 2026 in Review

ProShare Advisors sold out of Cardiff Oncology (CRDF) in Q1 2026, closing a stake of 11,328 shares — an estimated $31.8K sold.

ProShare Advisors first reported a position in CRDF in Q4 2024 and held it in 5 quarters. The position peaked at $49.9K in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • ProShare Advisors reported no remaining Cardiff Oncology position as of Q1 2026 after selling out during the quarter.
  • ProShare Advisors sold 11,328 Cardiff Oncology shares in Q1 2026, an estimated $31.8K.
  • ProShare Advisors first reported a position in Cardiff Oncology in Q4 2024 and held it in 5 quarters.
  • ProShare Advisors's Cardiff Oncology position peaked at $49.9K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.